Key facts
- This page summarizes Neil Josephson's Form 4 filing for Zymeworks BC Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Nov 2022, 20:00.
Neil Josephson - 10 Nov 2022 Form 4 Insider Report for Zymeworks BC Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 10 Nov 2022
- Net transaction value
- -$20,045
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2022, 20:00:43 UTC
- Prior SEC filing
- 05 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Dex, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Neil Josephson filed Form 4 for Zymeworks BC Inc. on 14 Nov 2022.
Change
- Previous filing in this sequence was filed on 05 Jul 2022.
- Current net transaction value: -$20,045.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZYME
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +5,885
- Change %
- +53%
- Price
- $0.000000
- Shares after
- 16,924
- Date
- 10 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
ZYME
transaction
Common Stock
Sale
- Transaction value
- $20,045
- Shares
- -2,475
- Change %
- -15%
- Price
- $8.10*
- Shares after
- 14,449
- Date
- 10 Nov 2022
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZYME
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -5,885
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 11,772
- Date
- 10 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 5,885
- Exercise price
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.
Footnote F2
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Footnote F4
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
Footnote F5
The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.
SEC remarks
On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer.